TE方案新辅助化疗前后60岁以上乳腺癌合并糖尿病患者肾功能指标的变化分析

摘要

目的 探讨分析60岁以上乳腺癌合并糖尿病患者在TE方案新辅助化疗前后血肌酐(Scr)、尿素氮(BUN)、血清胱抑素C(CysC)的变化规律及特征.方法 选取哈励逊国际和平医院86例60岁以上乳腺癌合并糖尿病患者,分析TE方案新辅助化疗前后Scr、BUN、CysC检测结果情况.结果 60岁以上乳腺癌合并糖尿病患者新辅助化疗后Scr、BUN、CysC检测结果均呈现增高趋势,Scr检测结果在新辅助化疗前后差异无统计学意义(P>0.05),BUN检测结果在新辅助化疗前后差异无统计学意义(P>0.05),CysC检测结果在新辅助化疗前后差异有统计学意义(P<0.05).结论 60岁以上乳腺癌合并糖尿病患者新辅助化疗后CysC升高,表明TE方案新辅助化疗对有糖尿病既往病史的乳腺癌患者的肾功能造成一定损害,监测乳腺癌患者新辅助化疗过程中肾功能的变化有重要临床指导意义.%ObjectiveTo investigate the change rules and characteristics of Scr, BUN and CysC in over 60-year breast cancer patients with diabetes mellitus before and after TE scheme neoadjuvant chemotherapy.Methods Eighty-six breast cancer patients over 60 years complicated with diabetes mellitus were selected from Harrison International Peace Hospital. Scr, BUN and CysC before and after TE scheme neoadjuvant chemotherapy were detected and analyzed.Results Scr, BUN and CysC detection results of the breast cancer patients with diabetes mellitus showed increasing trends after neoadjuvant chemotherapy. Scr and BUN detection results were not statistically different before and after neoadjuvant chemotherapy (P > 0.05), CysC detection results were significantly different before and after neoadjuvant chemotherapy (P < 0.05).ConclusionsIn over 60-year breast cancer patients with diabetes mellitus, CysC significantly increases after neoadjuvant chemotherapy, showing that TE scheme of neoadjuvant chemotherapy could induce certain renal damage to breast cancer patients with diabetes. Monitoring kidney function changes in the patients with breast cancer during the process of neoadjuvant chemotherapy has important clinical significance. Scr and BUN do not have significant changes before and after neoadjuvant chemotherapy.